Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00660218

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Sponsor: CTI BioPharma

Interventions cetuximab paclitaxel poliglumex radiation therapy (IMRT or 3D-CRT)

Updated 8 times since 2017 Last updated: Oct 29, 2021 Started: Mar 31, 2008 Primary completion: Dec 31, 2016 Completion: Apr 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00660218, this PHASE1/PHASE2 trial focuses on Carcinoma, Squamous Cell and remains completed. Sponsored by CTI BioPharma, it has been updated 8 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed
Jan 2021 — Dec 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

▶ Show 3 earlier versions

May 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Feb 2017 — May 2017 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CTI BioPharma
State University of New York - Upstate Medical University

Data source: State University of New York - Upstate Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Syracuse, United States